- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Stryker raises profit forecast on stronger demand for surgical devices
United States: Medical technology company Stryker Corp on Monday raised its full-year profit forecast, citing stronger demand for the company's surgical devices.Device makers, lately, have been reporting a recovery in sales as staff shortages ease and procedure volumes pick up in hospitals. Last week, peer Edwards Lifesciences Corp raised its sales and profit forecasts for 2023, citing...
United States: Medical technology company Stryker Corp on Monday raised its full-year profit forecast, citing stronger demand for the company's surgical devices.
Device makers, lately, have been reporting a recovery in sales as staff shortages ease and procedure volumes pick up in hospitals. Last week, peer Edwards Lifesciences Corp raised its sales and profit forecasts for 2023, citing strong demand for the company's artificial heart valves.
For the first quarter, Stryker posted a 11% rise in device sales in its medical surgery and neurotechnology unit, while sales in the orthopaedics and spine segment went up by 13%.
Excluding items, the device maker reported a profit of $2.14 per share for the quarter ended March 31, beating analysts' estimate of $2.00 per share, according to Refinitiv data. Net sales rose 12% to $4.78 billion, compared to estimates of $4.56 billion.
Stryker said supply chain pressures are gradually improving and it expects pricing to be relatively neutral for the year.
Read also: Stryker opens Neurovascular lab to accelerate stroke-related innovation in Asia Pacific
The company expects its 2023 organic net sales to grow between 8% and 9%, based on a strong order book for capital equipment and ongoing procedural recovery. It had previously expected a 7.0% to 8.5% sales growth in the year.
Stryker now expects a profit of between $10.05 and $10.25 per share, up from its prior forecast of $9.85 to $10.15 per share. Analysts expect a profit of $10.03 per share in 2023.
Read also: USFDA clears Stryker's Q Guidance System with Cranial Guidance Software
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751